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Essentials
• Isolated distal deep vein thrombosis (IDDVT) is fre-
quently associated with cancer.
• No study has specifically evaluated the long-term clini-
cal course of cancer-associated IDDVT.
• Patients with cancer-associated IDDVT are at very high
risk of symptomatic recurrence and death.
• We observed low rates of major bleeding during antic-
oagulation.
Summary. Background: Although isolated distal deep vein
thrombosis (IDDVT) is frequently associated with cancer,
no study has specifically evaluated the long-term clinical
course of IDDVT in this setting. Aim: To provide data
on the rate of recurrent venous thromboembolism (VTE),
major bleeding events and death in IDDVT patients with
active cancer. Patients and Methods: Consecutive patients
with active cancer and an objective IDDVT diagnosis
(January 2011 to September 2014) were included from
our files. We collected information on baseline character-
istics, IDDVT location and extension, VTE risk factors,
and type and duration of anticoagulant treat-
ment. Results: A total of 308 patients (mean age 66.2 [s-
tandard deviation (SD), 13.2 years]; 57.1% female) with
symptomatic IDDVT and a solid (n = 261) or hemato-
logic (n = 47) cancer were included at 13 centers. Cancer
was metastatic in 148 (48.1%) patients. All but three
(99.0%) patients received anticoagulant therapy, which
consisted of low-molecular-weight heparin in 288 (93.5%)
patients. Vitamin K antagonists were used for the long-
term treatment in 46 (14.9%) patients, whereas all others
continued the initial parenteral agent for a mean treat-
ment duration of 4.2 months (SD, 4.6 months). During a
total follow-up of 355.8 patient-years (mean,
13.9 months), there were 47 recurrent objectively diag-
nosed VTEs for an incidence rate of 13.2 events per 100
patient-years. During anticoagulant treatment, the annual
incidence of major bleeding was 2.0 per 100 patient-
years. Conclusions: Cancer patients with IDDVT have a
high risk of VTE recurrence. Additional studies are war-
ranted to investigate the optimal intensity and duration
of anticoagulant treatment for these patients.
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Background
Isolated distal deep vein thrombosis (IDDVT) accounts for
about half of all the diagnoses of deep vein thrombosis
(DVT) [1]. The clinical relevance of IDDVT is controver-
sial and, consequently, the suggested therapeutic approach
remains highly heterogeneous, ranging from anticoagulant
treatment to clinical and ultrasonographic follow-up [1,2].
In an early randomized study published in 1985, one of 23
(4%) patients with IDDVT receiving warfarin had a recur-
rent venous thromboembolic event (VTE) compared with
19 of 28 (68%) in the control group [3]. Despite some limi-
tations, including the small sample size and the use of an
outdated reference test to diagnose IDDVT, this study sug-
gested that IDDVT confers a non-negligible risk of recur-
rence when left untreated. These findings were later
supported by similar data from a number of cohort studies
[4–6], whereas the randomized DOTAVK study [7] and
two patient-level meta-analyses questioned the clinical rele-
vance of IDDVT, showing a cumulative rate of recurrent
VTE up to 5-fold lower than for proximal DVT [8,9].
These inconsistencies may be explained by differences in
study populations and management patterns [10–12].
Although most IDDVT may be truly self-limiting without
active treatment, the risk of progression or recurrence
appears to be increased in high-risk patients, defined by the
concomitance of major underlying risk factors [1,10–12]. In
this context, several studies have shown an increased risk
of recurrent VTE in IDDVT associated with cancer [4–7].
However, these studies included few patients with active
cancer, and none evaluated the long-term risk of VTE
recurrence in this specific population or assessed the poten-
tial benefits and risks of antithrombotic treatment. In the
absence of solid evidence from large prospective studies,
the American College of Chest Physicians (ACCP) guideli-
nes suggest the same approach as for proximal DVT for
patients with active cancer and IDDVT, with anticoagulant
therapy continued for at least 3 months or longer [2]. How-
ever, whether anticoagulant treatment should be continued
indefinitely in patients with active cancer and IDDVT
remains uncertain and in clinical practice the duration of
treatment in these patients is highly variable.
Given the paucity of data on the long-term clinical
course of IDDVT in patients with cancer, we carried out
a multicenter, retrospective cohort study with the aim of
evaluating the long-term risk of VTE recurrence, major
bleeding and mortality in cancer patients with acute,
symptomatic IDDVT.
Methods
Study population
This study was a multicenter, retrospective cohort study
of adult patients (age 18 years or older) with a diagnosis
of active cancer and symptomatic acute IDDVT referred
to the anticoagulation clinics of 13 Italian centers between
January 2011 and September 2014. Patients with con-
comitant proximal DVT or symptomatic pulmonary
embolism (PE) and those who were currently receiving
anticoagulant therapy for other indications were excluded.
Asymptomatic PE was not systematically searched for.
The diagnosis of IDDVT was objectively confirmed by
means of whole leg compression ultrasound using high-
resolution 5-MHz to 7.5-MHz linear transducers [13]. The
proximal deep veins were examined with the patient in
the supine position by applying gentle compression with
the probe along the deep venous system from the com-
mon femoral vein at the groin to the trifurcation of the
popliteal vein. The deep calf veins were examined down
to the ankle with a similar ultrasound procedure, with the
patient in the sitting position hanging the legs down. The
calf veins examined were the posterior tibial, peroneal,
gastrocnemius muscular and soleal veins. The criterion
for diagnosing proximal and calf DVT was the non-com-
pressibility of the vein in the transverse plane. Doppler
evaluation of the iliac veins was used to aid the diagnosis
in the case of suspected isolated iliac thrombosis.
Active cancer was defined by histologically or cytologi-
cally confirmed malignancy (with the exclusion of basal
cell carcinoma or non-melanoma skin cancer) with any of
the following: cancer diagnosis within the previous
6 months; recurrent, regionally advanced or metastatic
disease; treatment for cancer during the previous 6
months; or not in complete remission from a hematologi-
cal malignancy [14].
Data collection
Trained study personnel from each participating center
recorded baseline patient characteristics in an electronic
database. The following information was collected at the
time of IDDVT diagnosis: clinical characteristics (age,
sex, ethnicity and bodyweight); VTE risk factors (e.g. pre-
vious VTE, major trauma, surgery or hospitalization in
the previous month, or immobilization for more than
3 days); cancer stage and treatments such as ongoing or
recent chemotherapy, radiotherapy or hormonal therapy
in the previous month; and placement of a central venous
catheter.
All patients underwent regular follow-up visits or tele-
phone contacts at intervals of about 6 months up to
24 months after IDDVT diagnosis. The last follow-up
visit was performed in September 2016. During follow-up
visits, the treating oncologist or general practitioner
assessed vital status and verified the occurrence of throm-
boembolic and bleeding events.
Anticoagulant treatment
Because the study was non-interventional, no prespecified
therapeutic protocols were used and treatment decisions
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were left at the discretion of the treating physician. Based
on the findings from a recent study that suggested a simi-
lar efficacy and safety of a 6-week course of low-molecu-
lar-weight heparin (LMWH) and vitamin K antagonists
for the treatment of IDDVT [15], most centers involved
in the current study provided LMWH treatment for at
least 6 weeks.
Study outcomes
The primary study outcome was the composite of objec-
tively documented recurrent VTE, including symptomatic
recurrent IDDVT, incidental or symptomatic proximal
DVT of the lower limbs, incidental or symptomatic PE,
or DVT in other sites (e.g. upper extremities, cerebral
vein thrombosis and splanchnic vein thrombosis). Recur-
rent IDDVT was diagnosed in the presence of thrombosis
of a previously normal vessel or in a previously com-
pletely recanalized distal venous segment. Proximal DVT
was objectively confirmed using standard imaging tech-
niques, including compression ultrasonography, computer
tomography venography or magnetic resonance venogra-
phy; non-fatal PE was diagnosed by computed tomogra-
phy pulmonary angiography or ventilation-perfusion
scintigraphy. The primary safety outcome was major
bleeding, which was defined according to the Interna-
tional Society on Thrombosis and Haemostasis criteria
[16]. Secondary outcomes were clinically relevant non-
major bleeding and overall mortality. All study outcomes
were locally adjudicated.
Statistical analysis
Continuous data are presented with mean and standard
deviations (SD) or median and interquartile range
according to their distribution, after applying the Kol-
mogorov-Smirnov test. The number of recurrent VTEs is
expressed as percentage with 95% confidence intervals
(CIs) with continuity correction, and incidence rate, cal-
culated as the number of events per 100 patient-years of
observation. A multivariate Cox-regression analysis was
performed to estimate the hazard ratio (HR) and CI
associated with potential predictors of recurrent VTE,
which were associated with the outcome at univariate
analysis (P < 0.10) [17]. The following variables were
considered for the univariate analysis: age, sex, personal
and family history of VTE, obesity (body mass index
≥ 30 kg m2), site of cancer, presence of metastases,
ongoing cancer treatment and IDDVT extension. Inci-
dence of major bleeding events and mortality rate during
the follow-up period are expressed as percentage. The
Fine and Gray model was used to assess the time to
recurrence of VTE accounting for the competing risk of
death, using the same strategy adopted for Cox-regres-
sion analysis. The incidence of recurrent VTE was ana-
lyzed according to the intensity and duration of
anticoagulant treatment. The dose of parenteral treat-
ment was classified as prophylactic or therapeutic accord-
ing to drug labeling and prescription. All other doses
were classified as intermediate doses. Vitamin K antago-
nists at a target international normalized ratio between
2.0 and 3.0 were considered within the therapeutic group.
For the analysis on recurrent VTE by anticoagulant
treatment duration, we considered patients receiving
treatment (i) up to 6 weeks, which is the duration
advised for IDDVT secondary to transient risk factors
[1,15], (ii) up to 3 months, which is the duration sug-
gested by the ACCP guidelines [2], or (iii) longer than
3 months. IBM SPSS Statistics software, version 19
(SPSS, Inc., IBM corporation, U.S., Armonk, NY, USA)
was used for all the analyses. The Institutional Review
Board of the Coordinating Institution in Varese
approved the study and waived the need for written
informed consent, with a verbal consent to gather data in
a centralized database and contact patients on a regular
basis for study purposes.
Results
Population characteristics
Between January 2011 and September 2014, we included
308 patients (mean age 66.2 [SD 13.2] years; 57.1%
female) with acute symptomatic IDDVT and a solid
(n = 261) or hematologic (n = 47) cancer. At the time of
IDDVT diagnosis, the cancer was metastatic in 148
patients (48.1%). IDDVT involved the axial calf veins in
135 (43.8%) patients, the muscular veins in 200 (64.9%),
and it was bilateral in 22 (7.1%). IDDVT extended up to
the popliteal trifurcation in 39 (12.7%) patients. Clinical
presentation of IDDVT included pain in 183 (59.4%)
patients and edema in 176 (57.1%) patients, with a mean
interval of 5 days (range 0–30) between symptoms onset
and IDDVT diagnosis. Baseline characteristics are sum-
marized in Table 1.
Anticoagulant treatment
Three-hundred and five (99.0%) patients received antico-
agulant therapy, which consisted of LMWH in 288
(93.5%), fondaparinux in 15 (4.9%) and unfractionated
heparin in one case (0.3%). Full therapeutic or interme-
diate dose of parenteral antithrombotic therapy was used
in the vast majority of patients (93.5%). Vitamin K
antagonists with a target international normalized ratio
between 2.0 and 3.0 were used in 46 patients (14.9%) for
long-term treatment, whereas all others continued the
initial parenteral agent at prophylactic or half-therapeu-
tic doses for an overall mean treatment duration of
4.2 months (SD, 4.6 months; median, 3 months; range,
0–24 months). Ninety-three (30%) patients received up
to 6 weeks of treatment, 92 (30%) between 6 weeks and
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3 months, and 123 (40%) were anticoagulated for
3 months or longer.
Three patients did not receive any anticoagulant ther-
apy because they were judged to be at high risk of bleed-
ing by the treating physician. One patient with metastatic
gastric carcinoma and severe anemia as a result of tumor
infiltration of the intestinal wall underwent vena cava fil-
ter placement and died 2 days after the diagnosis of
IDDVT. Another patient with metastatic gastric carci-
noma was diagnosed with IDDVT during the course of
hospitalization for neoplastic cachexia and severe anemia
with concomitant antiplatelet therapy. The third patient
had multiple myeloma-associated severe thrombocytope-
nia (17 000 mL1). None of these three patients left
untreated developed recurrent VTE.
Clinical outcomes
During a total follow-up of 355.8 patient-years (mean
follow-up, 13.9 months), 47 patients had recurrent (a)
symptomatic VTE for an incidence rate of 13.2 events per
100 patient-years (95% CI, 9.9–17.6%; Table 2). We did
not consider recurrent incidental IDDVT as an outcome.
The prognostic value of these events is unclear and their
incidence would be inevitably influenced by the frequency
and accuracy of diagnostic tests applied in each center.
The overall recurrent-VTE-free survival after adjustment
for death as competing risk factor is shown in Fig. 1.
Thirty-three of the 47 recurrent VTEs were proximal
DVT or PE with or without DVT, or splanchnic vein
thrombosis. Forty VTE events were symptomatic,
whereas seven VTEs (three PEs, one proximal DVT of
the femoral vein and three splanchnic vein thrombosis)
were incidentally diagnosed by computed tomography
imaging performed for staging reevaluation after cancer
treatment. In the three incidental PEs the most proximal
pulmonary artery was the main pulmonary artery in two
cases and the lobar artery in one patient. Incidental
splanchnic vein thrombosis involved the portal vein in
two cases and the mesenteric vein in one. The annual inci-
dence of recurrent symptomatic VTE was of 11.2 per 100
patient-years (95% CI, 8.3–15.4%) and of proximal DVT
or PE with or without DVT 9.0 per 100 patient-years
(95% CI, 6.4–12.7%).
Sixteen (34%) recurrent VTEs occurred on treatment
during a mean of 2.9 months (IQR, 1.9–4.1) for an
annual incidence rate of 15.0 per 100 patient-years: four
patients were on oral anticoagulant therapy with vita-
min K antagonists, seven patients were receiving inter-
mediate-dose LMWH and five patients were on
therapeutic-dose LMWH. The remaining 31 (66%)
events occurred after anticoagulant treatment with-
drawal during a mean off-treatment period of
8.0 months (IQR, 3.0–14.0) for an incidence rate of
12.4 events per 100 patient-years.
Table 1 Baseline characteristics of the study population
Number of patients 308
Age (years), mean (SD) 66.2 (13.2)
Women, n (%) 176 (57.1%)
Obesity* 25 (8.1%)
Concomitant risk factors for VTE
Recent surgery or trauma 79 (25.6%)
In-patient/immobilization 45 (14.6%)
Prolonged bed rest 47 (15.3%)
Local or systemic infections 19 (6.2%)
Qualifying isolated distal deep venous thrombosis
Axial calf veins 135 (43.8%)
Muscular calf veins 149 (48.4%)
Medial gastrocnemius veins 113 (36.7%)
Lateral gastrocnemius veins 45 (14.6%)
Soleal veins 73 (23.7%)
Bilateral venous thrombosis 22 (7.1%)
More than one vein involved 127 (41.2%)
Personal history of VTE 45 (14.6%)
Family history of VTE 16 (5.2%)
Primary cancer site
Breast 54 (17.5%)
Gastrointestinal 51 (16.6%)
Pancreas 18 (5.8%)
Hepatic 9 (2.9%)
Lung 44 (14.3%)
Hematologic 47 (15.3%)
Prostate 17 (5.5%)
Brain 15 (4.9%)
Other 53 (17.2%)
Metastases 148 (48.1%)
Cancer therapy
Systemic chemotherapy 174 (56.5%)
Radiotherapy 20 (6.5%)
Hormonal therapy 36 (11.7%)
Initial anticoagulant therapy 305 (99%)
Low-molecular-weight heparin 288 (93.5%)
Fondaparinux 16 (5.2%)
Unfractionated heparin 1 (0.3%)
Vitamin K antagonists 46 (14.9%)
Duration of anticoagulant therapy (months), mean
(SD)
4.2 (4.6)
VTE, venous thromboembolism; SD, standard deviation. *Obesity
was defined as body mass index > 30 kg m2.
Table 2 Recurrent venous thromboembolic events, bleeding and
death during follow-up
Recurrent VTE 47 (15.3%)
Symptomatic 40
Proximal DVT or PE 25 (81%)
Proximal DVT 12
PE with or without DVT 13
Recurrent IDDVT 15 (4.9%)
Incidental 7 (2.3%)
Proximal DVT 1
PE 3
Splanchnic DVT 3
Major bleeding 7 (2.3%)
Clinically relevant non-major bleeding 24 (7.8%)
Death 138 (44.8%)
DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous
thromboembolism; IDDVT, isolated distal deep vein thrombosis.
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The rate of recurrent VTE both during anticoagulation
and after treatment withdrawal was similar in patients
who received prophylactic, intermediate or full therapeu-
tic-dose anticoagulation (P = 0.080 and P = 0.249).The
incidence of recurrent VTE after treatment withdrawal
was significantly higher in patients with IDDVT treated
for 6 weeks or less (15/92 patients, 16.3%) compared with
patients who received anticoagulant therapy for up to
3 months (9/92 patients, 9.8%) or longer (7/123, 5.7%)
(P = 0.038), and in particular, after adjustment for age
and sex and for other possible confounders, patients trea-
ted for 6 weeks or less had a higher risk of recurrence
(HR, 4.42; 95% CI, 1.75–11.15) compared to patients
treated for more than 3 months. There were no case of
heparin-induced thrombocytopenia during follow-up.
At univariate analysis, a personal history of VTE and
metastatic disease were associated with an increased risk
of VTE recurrence, whereas a diagnosis of gastrointestinal
cancer was associated with a lower risk of recurrence than
other cancer types. At multivariate analysis, only a per-
sonal history of VTE (HR, 2.15; 95% CI, 1.09–4.23) and
gastrointestinal cancer (HR, 0.17; 95% CI, 0.04–0.70)
remained as predictors. Multivariate analysis considering
death as a competing risk for VTE recurrence gave simi-
lar results, with an association with previous VTE and an
inverse relationship with gastrointestinal cancer (HR,
1.86; 95% CI, 0.95–3.63, and HR, 0.21; 95% CI, 0.05–
0.84, respectively).
During a mean anticoagulant treatment duration of
4.2 months, seven patients (2.3%) had a major bleeding
event for an incidence of 2.0 per 100 patient-years (95%
CI, 1.0–5.0%). Major bleeding involved the upper or
lower gastrointestinal tract in three patients, the urinary
tract in two cases of gross hematuria, and the retroperi-
toneum in one patient. One patient with glioblastoma
had intracranial bleeding during LMWH therapy. All but
one of these patients had three or more bleeding risk
factors, including previous major bleeding,
thrombocytopenia and renal insufficiency. During the
study, 138 patients died (44.8%) after a median time of
6 months (range, 1–24 months) since IDDVT diagnosis.
Forty-one patients (29.7%) died within 3 months. One
patient died one week after recurrent VTE and another
patient had fatal major gastrointestinal bleeding. The
mortality rate was higher in patients who had recurrent
VTE than those who did not (93.5 per 100 patient-years
vs. 34.7 per 100 patient-years, P < 0.05).
Discussion
The results of this study show that patients with acute
symptomatic IDDVT and active cancer are usually trea-
ted for a limited period of time and are at a relatively
high risk of recurrent VTE (13.2% per year), with about
two-thirds of events occurring after anticoagulant
treatment withdrawal. Anticoagulant treatment was well
tolerated with a relatively low incidence of anticoagulant-
related major bleeding events.
The clinical relevance of IDDVT remains uncertain
[18], and most of these below-knee thrombi are supposed
to be self-limited [1,2]. However, the risk of progression
to proximal DVT or VTE recurrence may be increased in
high-risk subgroups with persistent VTE risk factors
[1,4–6]. Active cancer is a well-known major risk factor
for first and recurrent VTE, accounting for about 20% of
all VTEs [19]. Although a number of studies have sug-
gested that active cancer may increase the risk of recur-
rent VTE in IDDVT, it should be realized that none of
these studies specifically focused on cancer patients, and
most had a relatively small size, lacked information on
the type and duration of anticoagulant treatment, and
presented significant methodological limitations [4–7,20–
22]. To our knowledge, this is the largest cohort of
IDDVT in patients with active cancer with long-term fol-
low-up. The recent ACCP guidelines suggest for IDDVT
the same therapeutic approach as for acute proximal
DVT in the presence of active cancer, which translates
into LMWH treatment for at least 3 to 6 months for
most patients [2]. This study found an overall incidence
rate of 13.2 recurrent VTEs per 100 patient-years and the
rate of recurrence at 6 months (25.1 per 100 patient-years;
95% CI, 17.9–35.3%) is even higher than the recurrence
rate observed in cancer patients with proximal DVT or
PE [14]. Patients receiving 6 weeks of treatment were
exposed to a significantly higher risk of developing recur-
rent VTE than patients treated for longer periods.
Because of the observational design of the study, the lack
of a control group and the possibility of an unbalanced
distribution of VTE risk factors, these findings remain
hypothesis generating. However, together with the obser-
vation of a high event rate after treatment discontinua-
tion, these results strongly suggest that patients with
active cancer and IDDVT benefit from long-term antico-
agulation. As expected, patients with a previous VTE had
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an increased risk of recurrence, whereas gastrointestinal
cancer appeared to have a lower risk. These associations
should be interpreted with caution given the small num-
ber of patients.
The incidence of anticoagulant-related major bleeding
in patients with IDDVT varied broadly from 0% to 6%,
possibly as the consequence of differences in study popu-
lations, anticoagulant regimens and durations of follow-
up [22]. We observed an overall low risk of anticoagu-
lant-related major bleeding, in agreement with other stud-
ies of IDDVT [5] and with the results of a recent large
randomized trial on the treatment of proximal DVT or
PE in patients with cancer [14].
Our study has some limitations that deserve to be
acknowledged. First, the study did not impose a specific
treatment protocol for IDDVT. Over half (54%) of our
patients were treated with LMWH at full therapeutic dose
for 2–4 weeks followed by half-therapeutic doses according
to the results of a previous study, which showed that this
regimen was as effective and safe as vitamin K antagonists
in patients with IDDVT [15]. However, the evidence on the
efficacy and safety of this treatment regimen is limited and
conflicting [23]. We were not able to confirm the efficacy of
this regimen because of the significant heterogeneity of
treatments in our population. Second, recurrent VTE
events were not centrally adjudicated, which may have
potentially resulted in an overestimation of their incidence.
However, objective confirmation of all outcome events was
mandatory for all centers, and this may have limited verifi-
cation bias. Third, the accuracy of ultrasonography for
IDDVT is significantly lower than for proximal DVT and
some of the cases may represent, in fact, false positives. In
addition, compression ultrasonography was not performed
systematically in all centers at regular time intervals during
follow-up. Although we cannot exclude that some asymp-
tomatic IDDVT progressed to proximal DVT or PE, this
risk may have been minimized by computed tomography
scans ordered during follow-up by the treating oncologist
to assess response to cancer treatment. Some of the recur-
rent events incidentally detected in the current study may
in fact represent IDDVT progressions. Fourth, we
restricted the number of VTE predictors by stepwise selec-
tion; however, the relatively low number of events may still
be considered as a limitation of the multivariable analysis.
We were not able to address the potential influence of con-
founders such as cancer stage or cancer progression as
these data were not collected homogeneously or were not
available in some centers. Fifth, our results were not
adjusted for different chemotherapies because this was out-
side the objectives of our study. Finally, about half of the
patients died during the study. Autopsy was not manda-
tory and it cannot be excluded that some deaths attributed
to cancer progression were fatal PEs.
The strengths of this study include the large size of the
population and duration of follow-up, which make this
the largest cohort of active cancer patients with IDDVT.
Finally, results were substantially unchanged when the
potential competing risk of death was taken into account.
In conclusion, patients with cancer-associated IDDVT
have a significant risk of recurrent VTE. The high inci-
dence of recurrence both during anticoagulation and at
treatment withdrawal strongly points to the need for
additional studies to establish the optimal intensity and
duration of treatment in these patients.
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